Six supermarket foods that 'work like weight-loss jabs' for fraction of price
While an estimated 1.5 million people in the UK are taking weight loss drugs in a bid to shed the pounds, a nutritionist has revealed that the secret to weight loss is probably hiding in your fridge.
GLP-1 weight loss drugs like Mounjaro have become popular in the UK in recent months, but have also been linked to some health concerns as medics warn users to be careful when purchasing the jabs online. And according to a nutritionist, there's no need to take the pricey medication.
Maria AbiHanna, from Food Label Maker, claims there's a cheaper, easier way that starts in your local supermarket. "These drugs work by slowing digestion and activating the body's natural 'I'm full' hormones like GLP-1," AbiHanna says. "But certain foods can do the same thing naturally, and without the nausea."
Here's what to purchase next time you are at the supermarket if you want to feel fuller for longer while switching to a healthier diet.
1. Protein: Eggs, Greek yogurt, edamame
Protein is key in feeling fuller for longer, helping to pack in those late night or middle of the day snack cravings. Two eggs pack 13g of protein, while Greek yogurt delivers around 10g, and both keep hunger at bay by activating satiety hormones.
Edamame is another protein-packed winner that doubles as a healthy snack. "Protein turns off cravings before they even start," says AbiHanna.
2. Fibre: Chia seeds, lentils, oats
According to AbiHanna, fibre is the secret to staying full for longer while also aiding in digestion.
It helps to slow down digestion and keep blood sugar steady - just like GLP-1 meds. Chia seeds expand in your gut, while lentils and oats pack fiber and resistant starch for long-lasting satisfaction.
A simple sprinkling of chia seeds into a smoothie or overnight oats can offer a big fibre boost.
3. Healthy fats: Avocados, peanut butter
Despite often being seen as "bad" - fat can actually be beneficial for weight loss. Avocados and peanut butter are full of healthy monounsaturated fats that slow digestion and keep you satisfied.
"Fat plus fiber is a hunger-fighting dream team," says AbiHanna. Try avocado with eggs, or peanut butter with apple slices for a smart snack.
4. Smart carbs: Sweet potatoes, quinoa, lentils
Not all carbs are created equal. These slow-burning carbs digest gently, keeping energy stable without the dreaded sugar crash.
"Think long-term fuel, not fast-burning fire," AbiHanna explains.
5. Vegetables: Leafy greens, broccoli, cucumbers
According to AbiHanna, loading up on high-volume, low-calorie veggies can trick your stomach into feeling full.
Leafy greens, broccoli, and cucumbers stretch your stomach, triggering that "I'm done" feeling faster. Add them to every meal to feel fuller on fewer calories.
6. Snacks: Matcha, green Tea, fibre fat combos
Snacking doesn't have to ruin your progress - if you choose wisely. matcha and green tea offer mild appetite suppression, while fat-fiber combos like apple slices with almond butter keep cravings away.
"If it stabilises your blood sugar, it stabilises your hunger," AbiHanna explains.
GLP-1 meds like Mounjaro might be trending, but there are plenty of natural ways to shed weight. The right foods can flip the same fullness switch - without a prescription or side effects .
"This isn't about dieting or willpower," says AbiHanna. "It's about working with your biology, not against it."
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mirror
13 minutes ago
- Daily Mirror
Filthiest household item 'dirtier than your toilet' as GP issues stark warning
Brits are warned to keep an eye on certain household items used every day as they may contain thousands of harmful germs and bacteria despite keeping them 'clean' Even if you keep your kitchen spotless - there is one item that may be holding onto millions of germs and filthier than a toilet seat. There is an estimated 200,000 different species of microbes in homes and some unexpected household items are breeding grounds for different bacteria. According to rubbish clearance experts and NHS GP Dr Hana Patel, items such as kitchen sponges, towels and toothbrush holders are among the biggest culprits in homes. While sponges are a staple for washing up, they are also one of the dirtiest items in the home. They're porous, which means they harbour damp, and combined with food particles, it's the perfect place for bacteria to grow and thrive including E. coli and Salmonella which could lead to infections. The experts recommend to avoid letting these germs harbour on your sponge and build up, to replace your sponge every 1-2 weeks as needed, or when the sponge begins to look worn. Toothbrush holders are also another breeding ground for bacteria - particularly enclosed ones. They can provide the perfect moisture trap for bacteria to grow as toothbrushes are often damp when placed in the holder, making it a moist environment with the potential for mould growth if not frequently cleaned. They can also be exposed to airborne bacteria in the bathroom, such as that from toilet flushing which can release faecal particles. Dr Hana Patel warns: "Toothbrushes which are kept in air conditions have less bacteria than those which are kept closed, and the bacterial growth is 70% higher in wet and protected environments. "The wet environment in the bathroom, where toothbrushes are usually kept, may facilitate the bacterial growth and the crossed contamination, especially that which happens through the aerosols produced during the water passing in lavatories, with enteric types and pseudomonas from the toilets and sanitary drainage." Always ensure your toothbrush is dry before putting it in the holder, and make sure you clean the holder regularly to prevent mould and bacteria build up. The experts also urge people to avoid putting the holder inside an enclosed cupboard or container, as this will trap moisture, limit ventilation, and promote mould and bacteria growth. Reusable bottles are also on the list and while they're good for the environment, these bottles can be a breeding ground for bacteria as they're often moist, providing a breeding ground for bacteria from the user's mouth, food particles, and hands. Without regular and sufficient cleaning, these bacteria can lead to illness. It is advised to ideally wash these bottles daily, to avoid any bacteria growth or moisture build up. Pay particular attention to hard to clean areas such as straws and small crevices, as this is where bacteria can grow if not adequately cleaned. Lastly, bathroom towels are also a risk. Studies have found that a third of people only wash their towels once a month, but this may not be enough. Bathroom towels are often left in damp, warm bathrooms, meaning they have the perfect environment for bacteria and mould growth. Many people believe them to be clean as they are used to dry clean hands, but germs and mould can thrive on our damp towels, and the dampness itself could create problems, as Dr Hana Patel explains: "There are possibly millions of mould species on earth. The rare species that cause diseases do so by triggering allergies or asthma, or may be involved in hypersensitivity diseases. 'Even if visible mould is not present, dampness alone can increase the risk of health problems. Excessive moisture can promote the growth of microorganisms such as mould and other fungi, certain species of house dust mites, bacteria or viruses." To prevent mould growth, Clear It Waste recommends that shower towels be washed every 3-5 uses or a minimum of once a week , and hand towels should be changed every two to three days due to frequency of use.
Glasgow Times
2 hours ago
- Glasgow Times
Type 2 diabetes patients set for major shake-up in care
The health service should move from a one-size-fits-all approach of starting everyone on the same medication, to more personalised care that aims to prevent complications like heart failure and heart attacks, according to new draft guidance from the National Institute for Health and Care Excellence (Nice). This includes making newer type 2 diabetes drugs, known as SGLT-2 inhibitors, a first-line treatment option in a move that could eventually help save tens of thousands of lives. SGLT-2 inhibitors, which include canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin, are once-a-day tablets that reduce blood sugar levels by helping the kidneys remove glucose, which is passed from the body through urine. However, analysis by Nice found these drugs are under-prescribed. The new guidelines recommend patients who cannot tolerate metformin – the first-choice in type 2 diabetes medication – should start with an SGLT-2 inhibitor on its own. The decision comes after evidence suggested these drugs protect the heart and kidneys as well as controlling blood sugar, Nice said. It is estimated the change could save almost 22,000 lives once uptake reaches 90% of the population. Nice also suggests some groups of patients would also benefit from GLP-1 receptor agonists such as liraglutide or semaglutide sooner, rather than keeping them for the later stages of treatment. Semaglutide, sold under the brand name Ozempic, is licensed in the UK to treat type 2 diabetes, while its other brand – Wegovy – is also used by the NHS to help obese people lose weight. Professor Jonathan Benger, deputy chief executive and chief medical officer at Nice, said: 'This guidance means more people will be offered medicines where it is right to do so to reduce their future risk of ill health. 'This represents a significant evolution in how we approach type 2 diabetes treatment. 'We're moving beyond simply managing blood sugar to taking a holistic view of a person's health, particularly their cardiovascular and kidney health. 'The evidence shows that certain medicines can provide important cardiovascular benefits, and by recommending them as part of initial treatment, we could help prevent heart attacks, strokes and other serious complications before they occur. 'This is particularly important given that cardiovascular disease is the leading cause of death in people with type 2 diabetes.' Around 4.6 million people in the UK are living with diabetes, with nine in 10 of those having type 2. However, it is estimated that a further 1.3 million people may have undiagnosed type 2 diabetes. Nice analysed the records of 590,000 people and found SGLT-2 inhibitors are under-prescribed, particularly to women, older people, and black patients. Prof Benger added: 'The evidence from our analysis is clear. There are prescribing gaps that need to be addressed. 'The guideline update published today will help to increase equitable uptake of SGLT-2 inhibitors, which we know can prevent serious health complications.' Dr Waqaar Shah, chairman of the guideline committee, added: 'We know that SGLT-2 inhibitors are currently under-prescribed, and our health economics analysis shows that people living in the most deprived areas would particularly benefit from universal access to these treatments. 'These recommendations could help reduce health inequalities while providing better outcomes for everyone.' Elsewhere, the draft guidance suggests different treatments for diabetes patients with certain characteristics or health conditions. These include adults with cardiovascular disease, who should be offered a triple therapy including a GLP-1 receptor agonist. Meanwhile, adults diagnosed with type 2 diabetes before 40 should be offered dual therapy before a GLP-1 receptor agonist is considered, while patients with chronic kidney disease should have tailored recommendations based on their kidney function. A public consultation on the new Nice guidelines is open until October 2. Douglas Twenefour, head of clinical at Diabetes UK, said: 'This long-awaited announcement propels type 2 diabetes treatment into the 21st century. 'Boosting access to newer treatments will be transformative for people with type 2 diabetes, while ensuring the UK keeps pace with the global momentum in treating the condition. 'The majority of people with type 2 diabetes are not currently taking the most effective medication for them, putting them at risk of devastating diabetes-related complications. 'Diabetes is a leading cause of cardiovascular disease, and tailoring treatment based on individual risk could protect thousands against heart attacks and kidney disease. 'These guidelines could go a long way to easing the burden of living with this relentless condition, as well as helping to address inequities in type 2 diabetes treatments and outcomes.'
North Wales Chronicle
2 hours ago
- North Wales Chronicle
Type 2 diabetes patients set for major shake-up in care
The health service should move from a one-size-fits-all approach of starting everyone on the same medication, to more personalised care that aims to prevent complications like heart failure and heart attacks, according to new draft guidance from the National Institute for Health and Care Excellence (Nice). This includes making newer type 2 diabetes drugs, known as SGLT-2 inhibitors, a first-line treatment option in a move that could eventually help save tens of thousands of lives. SGLT-2 inhibitors, which include canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin, are once-a-day tablets that reduce blood sugar levels by helping the kidneys remove glucose, which is passed from the body through urine. However, analysis by Nice found these drugs are under-prescribed. The new guidelines recommend patients who cannot tolerate metformin – the first-choice in type 2 diabetes medication – should start with an SGLT-2 inhibitor on its own. The decision comes after evidence suggested these drugs protect the heart and kidneys as well as controlling blood sugar, Nice said. It is estimated the change could save almost 22,000 lives once uptake reaches 90% of the population. Nice also suggests some groups of patients would also benefit from GLP-1 receptor agonists such as liraglutide or semaglutide sooner, rather than keeping them for the later stages of treatment. Semaglutide, sold under the brand name Ozempic, is licensed in the UK to treat type 2 diabetes, while its other brand – Wegovy – is also used by the NHS to help obese people lose weight. Professor Jonathan Benger, deputy chief executive and chief medical officer at Nice, said: 'This guidance means more people will be offered medicines where it is right to do so to reduce their future risk of ill health. 'This represents a significant evolution in how we approach type 2 diabetes treatment. 'We're moving beyond simply managing blood sugar to taking a holistic view of a person's health, particularly their cardiovascular and kidney health. 'The evidence shows that certain medicines can provide important cardiovascular benefits, and by recommending them as part of initial treatment, we could help prevent heart attacks, strokes and other serious complications before they occur. 'This is particularly important given that cardiovascular disease is the leading cause of death in people with type 2 diabetes.' Around 4.6 million people in the UK are living with diabetes, with nine in 10 of those having type 2. However, it is estimated that a further 1.3 million people may have undiagnosed type 2 diabetes. Nice analysed the records of 590,000 people and found SGLT-2 inhibitors are under-prescribed, particularly to women, older people, and black patients. Prof Benger added: 'The evidence from our analysis is clear. There are prescribing gaps that need to be addressed. 'The guideline update published today will help to increase equitable uptake of SGLT-2 inhibitors, which we know can prevent serious health complications.' Dr Waqaar Shah, chairman of the guideline committee, added: 'We know that SGLT-2 inhibitors are currently under-prescribed, and our health economics analysis shows that people living in the most deprived areas would particularly benefit from universal access to these treatments. 'These recommendations could help reduce health inequalities while providing better outcomes for everyone.' Elsewhere, the draft guidance suggests different treatments for diabetes patients with certain characteristics or health conditions. These include adults with cardiovascular disease, who should be offered a triple therapy including a GLP-1 receptor agonist. Meanwhile, adults diagnosed with type 2 diabetes before 40 should be offered dual therapy before a GLP-1 receptor agonist is considered, while patients with chronic kidney disease should have tailored recommendations based on their kidney function. A public consultation on the new Nice guidelines is open until October 2. Douglas Twenefour, head of clinical at Diabetes UK, said: 'This long-awaited announcement propels type 2 diabetes treatment into the 21st century. 'Boosting access to newer treatments will be transformative for people with type 2 diabetes, while ensuring the UK keeps pace with the global momentum in treating the condition. 'The majority of people with type 2 diabetes are not currently taking the most effective medication for them, putting them at risk of devastating diabetes-related complications. 'Diabetes is a leading cause of cardiovascular disease, and tailoring treatment based on individual risk could protect thousands against heart attacks and kidney disease. 'These guidelines could go a long way to easing the burden of living with this relentless condition, as well as helping to address inequities in type 2 diabetes treatments and outcomes.'
